Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Rating of “Moderate Buy” from Brokerages

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has been given a consensus recommendation of “Moderate Buy” by the six analysts that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $57.50.

A number of research firms recently issued reports on COLL. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Weiss Ratings downgraded shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, March 5th. Truist Financial raised shares of Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday. Needham & Company LLC reissued a “buy” rating and issued a $56.00 price target (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday, March 19th. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, March 20th.

Collegium Pharmaceutical Stock Performance

Collegium Pharmaceutical stock opened at $34.65 on Wednesday. The company has a quick ratio of 1.62, a current ratio of 1.71 and a debt-to-equity ratio of 2.47. The company has a market capitalization of $1.12 billion, a PE ratio of 16.99 and a beta of 0.74. The firm has a fifty day simple moving average of $34.08 and a two-hundred day simple moving average of $40.34. Collegium Pharmaceutical has a twelve month low of $29.11 and a twelve month high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.52 by $0.24. The firm had revenue of $193.52 million during the quarter, compared to the consensus estimate of $184.47 million. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The company’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.49 earnings per share. Research analysts expect that Collegium Pharmaceutical will post 6.8 EPS for the current year.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of hedge funds and other institutional investors have recently bought and sold shares of COLL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Collegium Pharmaceutical by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company’s stock worth $569,000 after purchasing an additional 825 shares during the period. Millennium Management LLC grew its holdings in Collegium Pharmaceutical by 248.5% in the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after purchasing an additional 461,914 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Collegium Pharmaceutical by 7.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,014 shares of the specialty pharmaceutical company’s stock worth $2,120,000 after purchasing an additional 4,625 shares during the period. Jane Street Group LLC grew its holdings in Collegium Pharmaceutical by 218.7% in the first quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company’s stock worth $3,926,000 after purchasing an additional 90,255 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in Collegium Pharmaceutical by 3.7% in the second quarter. JPMorgan Chase & Co. now owns 72,068 shares of the specialty pharmaceutical company’s stock worth $2,131,000 after purchasing an additional 2,592 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.